Lepu Biopharma (2157.HK) announces 2025 interim results
Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.
August 21, 2025
by ACN Newswire
Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum
Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum").
August 20, 2025
by Henlius
InnoCare Releases 2025 Interim Results and Business Highlights
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.
August 20, 2025
by PharmaSources
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate JSKN003 has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ).
July 29, 2025
by PR Newswire
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.
July 4, 2025
by PharmaSources
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field?
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
April 15, 2025
by Kevin
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
Henlius reported 2024 results with rising revenue and profit. It advanced in oncology, expanded globally, and made pipeline progress.
March 25, 2025
by PR Newswire
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC
Alphamab Oncology and CSPC jointly announced that anti-HER2 biparatopic ADC JSKN003 has been granted Breakthrough Therapy Designation by the CDE of the NMPA.
March 18, 2025
by PR Newswire
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan At 2025 ASCO Genitourinary Cancers Symposium
Study Results Abstracts From Aac-TMT At 2025 ASCO Genitourinary Cancers Symposium
February 13, 2025
by PR Newswire
Alphamab Oncology Announces the Study for Ovarian Cancer
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
February 13, 2025
by PR Newswire
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
January 23, 2025
by Yi
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
Samsung Biologics (KRX: 207940.KS) announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
January 15, 2025
by PRNewswire